ArticleCureus2024
Progressive Familial Intrahepatic Cholestasis Type 2 in an Infant: Diagnostic Challenges and Multidisciplinary Management.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Polymer-Based Electrochemical Sensors for the Diagnosis of Neurodegenerative Diseases.Cellular and molecular neurobiology · 2025Review
Corrections and comments
- Retraction · 2025-10-13Concerns/Issues about Authorship/Affiliation · Investigation by Journal/Publisher · Objections by Author(s) · Unreliable Results and/or Conclusions ·
- Retracted
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Progressive familial intrahepatic cholestasis type 2 (PFIC2) is a rare genetic disorder characterized by severe intrahepatic cholestasis, which often manifests in infancy with progressive liver dysfunction. We present the case of a 3-month-old infant with a one-month history of jaundice, vomiting, and bloody stools, presenting a unique set of diagnostic challenges. Initial clinical and laboratory findings indicated significant liver dysfunction, prompting further imaging and genetic analysis. An abdominal ultrasound revealed hepatomegaly with a coarse liver texture, while a hepatobiliary iminodiacetic acid (HIDA) scan ruled out biliary atresia. Ultimately, genetic testing confirmed a mutation in the ABCB11 gene, diagnostic of PFIC2. Management included total parenteral nutrition to support growth, ursodeoxycholic acid to improve bile flow, and rifampicin to alleviate pruritus. Due to the severity of the disease, a liver transplant is planned as the definitive treatment following stabilization through supportive care. This case underscores the importance of a high index of suspicion, timely genetic testing, and a multidisciplinary approach in managing PFIC2 to optimize patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.